Skip to main content

Table 3 The attributable risks for every individual risk factors and the combinations of tumor-related factors and patient-related factors in EMM and LMM group

From: Analysis of risk characteristics for metachronous metastasis in different period of nasopharyngeal carcinoma

Categories

Factors

AR in EMM group

AR in LMM group

Tumor

T-stage

78.19%

20.19%

43.85%

3.68%

N-stage

67.25%

49.11%

Pre-EB

2.81%

-18.04%

Post-EB

14.28%

2.19%

Patient

Sex

26.07%

18.50%

39.97%

6.11%

Age

-11.17%

0.36%

Pre-NLR

14.54%

4.62%

Pre-HB

9.60%

19.77%

Pre-PLR

3.74%

9.57%

Post-HB

-9.79%

7.76%

  1. Abbreviations: AR attributable risks, EMM early metachronous metastasis (metastasis within 2 years after treatment), LMM late metachronous metastasis (metastasis beyond 2 years after treatment), Pre-NLR neutrophil-to-lymphocyte ratio before treatment, Pre-HB hemoglobin before treatment, Pre-PLR platelet-to-lymphocyte ratio before treatment, Pre-EBV DNA Epstein-Barr virus DNA before treatment, Post-HB hemoglobin after chemoradiotherapy, Post-EBV DNA Epstein-Barr virus DNA after chemoradiotherapy